Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, United States.
Mol Pharm. 2012 Mar 5;9(3):581-90. doi: 10.1021/mp200460u. Epub 2012 Feb 22.
We have recently reported the interplay between apparent aqueous solubility and intestinal membrane permeability, showing the trade-off between the two when using cyclodextrin- and surfactant-based systems as solubility-enabling formulations. In these cases, the decreased permeability could be attributed directly to decreased free fraction of drug due to the complexation/micellization inherent in these solubilization methods. The purpose of this study was to investigate the direct solubility-permeability interplay, using formulations in which complexation is not the mechanism for increased solubilization. The apparent aqueous solubility (S(aq)) and rat intestinal permeability (P(eff)) of the lipophilic drug progesterone were measured in systems containing various levels of the cosolvents propylene glycol and PEG-400, since this solubilization method does not involve decreased free fraction. Thermodynamic activity was maintained equivalent in all permeability studies (75% equilibrium solubility). Both cosolvents increased progesterone S(aq) in nonlinear fashion. Decreased P(eff) with increased S(aq) was observed, despite the constant thermodynamic activity, and the nonrelevance of free fraction. A mass-transport analysis was developed to describe this interplay. The model considers the effects of solubilization on the membrane permeability (P(m)) and the unstirred water layer (UWL) permeability (P(aq)), to predict the overall P(eff) dependence on S(aq). The analysis revealed that (1) the effective UWL thickness quickly decreases with ↑S(aq), such that P(aq) markedly increases with ↑S(aq); (2) the apparent membrane/aqueous partitioning decreases with ↑S(aq), thereby reducing the thermodynamic driving force for permeability such that ↓P(m) with ↑S(aq); (3) since ↑P(aq) and ↓P(m) with ↑S(aq), the UWL is shorted out and P(eff) becomes membrane control with ↑S(aq). The model enabled excellent quantitative prediction of P(eff) as a function of S(aq). This work demonstrates that a direct trade-off exists between the apparent solubility and permeability, which must be taken into account when developing solubility-enabling formulations to strike the optimal solubility-permeability balance, in order to maximize the overall oral absorption.
我们最近报道了表观水溶性和肠道膜通透性之间的相互作用,当使用环糊精和表面活性剂基系统作为增溶制剂时,显示出两者之间的权衡。在这些情况下,通透性的降低可以直接归因于由于这些增溶方法固有的络合/胶束化,药物的游离分数降低。本研究的目的是研究直接的溶解度-通透性相互作用,使用的制剂中复合物形成不是增加溶解度的机制。在含有不同水平的共溶剂丙二醇和 PEG-400 的系统中测量亲脂性药物孕酮的表观水溶解度(S(aq))和大鼠肠道通透性(P(eff)),因为这种增溶方法不涉及游离分数的降低。在所有通透性研究中保持热力学活性等效(75%平衡溶解度)。两种共溶剂以非线性方式增加孕酮 S(aq)。尽管热力学活性不变,并且游离分数无关紧要,但观察到随着 S(aq)的增加,P(eff)降低。开发了一种质量传递分析来描述这种相互作用。该模型考虑了增溶对膜通透性(P(m))和未搅动水层(UWL)通透性(P(aq))的影响,以预测整体 P(eff)对 S(aq)的依赖性。分析表明:(1)随着 S(aq)的增加,有效 UWL 厚度迅速减小,使得 P(aq)随着 S(aq)的增加而显著增加;(2)随着 S(aq)的增加,表观膜/水分配减少,从而降低了通透性的热力学驱动力,导致 P(m)随着 S(aq)的增加而降低;(3)由于 P(aq)和 P(m)随着 S(aq)的增加而增加,UWL 被短路,并且随着 S(aq)的增加,P(eff)成为膜控制。该模型能够对 P(eff)作为 S(aq)的函数进行出色的定量预测。这项工作表明,表观溶解度和通透性之间存在直接的权衡,在开发增溶制剂以达到最佳溶解度-通透性平衡以最大限度地提高整体口服吸收时,必须考虑到这一点。